• 1
    Gill VS, Lima VD, Zhang W et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50: 98105.
  • 2
    Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis 2011; 53: 600604.
  • 3
    Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321333.
  • 4
    Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 38793884.
  • 5
    Sire JM, Vray M, Merzouk M et al. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr 2011; 56: 239243.
  • 6
    Doyle T, Smith C, Vitiello P et al. Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54: 724732.
  • 7
    Pugliese P, Cuzin L, Cabie A et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009; 10: 504511.
  • 8
    Saune K, Delaugerre C, Raymond S et al. Analytical sensitivity of three real-time PCR assays for measuring subtype B HIV-1 RNA. J Clin Virol 2013; 57: 8083.
  • 9
    Bonora S, Nicastri E, Calcagno A et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81: 400405.
  • 10
    Haim-Boukobza S, Morand-Joubert L, Flandre P et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011; 25: 341344.
  • 11
    Benzie AA, Bansi LK, Sabin CA et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007; 21: 14231430.
  • 12
    Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE 2009; 4: e7196.
  • 13
    Lima VD, Bangsberg DR, Harrigan PR et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55: 460465.
  • 14
    Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004; 5: 125131.
  • 15
    Cooper CL, Mills E. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection. Int J STD AIDS 2007; 18: 546550.
  • 16
    Gandhi RT, Deeks SG. Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough? Clin Infect Dis 2012; 54: 733775.
  • 17
    Palmer S, Wiegand AP, Maldarelli F et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 45314536.